help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on October 3, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1121
A more recent version of this article appeared on October 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/10/3697    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow View responses
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wierman, M. E.
Right arrow Articles by Santoro, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wierman, M. E.
Right arrow Articles by Santoro, N.

Submitted on May 24, 2006
Accepted on July 19, 2006

Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline

Margaret E. Wierman*, Rosemary Basson, Susan R. Davis, Sundeep Khosla, Karen K. Miller, William Rosner, and Nanette Santoro

University of Colorado at Denver and Health Sciences Center (M.E.W.), Aurora, Colorado 80010; University of British Columbia (R.B.), Vancouver, Canada V6T 1Z4; Alfred Hospital/Monash University (S.R.D.), Melbourne, Victoria 3181, Australia; Mayo Clinic (S.K.), Rochester, Minnesota 55905; Massachusetts General Hospital (K.K.M.), Boston, Massachusetts 02114; St. Luke's/Roosevelt Hospital Center (W.R.), New York, New York 10019; and Albert Einstein College of Medicine (N.S.), Bronx, New York 10461

* To whom correspondence should be addressed. E-mail: margaret.wierman{at}uchsc.edu.

Objective: The objective was to provide guidelines for the therapeutic use of androgens in women.

Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.

Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase "we recommend") or 2 (weak recommendation, associated with the phrase "we suggest"). The quality of the evidence is indicated by cross-filled circles, such that {oplus}{circ}{circ}{circ} denotes very low quality evidence, {oplus}{oplus}{circ}{circ} low quality, {oplus}{oplus}{oplus}{circ} moderate quality, and {oplus}{oplus}{oplus}{oplus} high quality. Each recommendation is followed by a description of the evidence.

Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society's Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes.

Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.
Key words: testosterone in women • sexual dysfunction • surgical menopause • cognition • mood • bone • body composition • cardiovascular and metabolic effects • risks and benefits




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
R. Basson
Testosterone Supplementation to Improve Women's Sexual Satisfaction: Complexities and Unknowns
Ann Intern Med, April 15, 2008; 148(8): 620 - 621.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. A. Martin, R. J. Chang, D. A. Ehrmann, L. Ibanez, R. A. Lobo, R. L. Rosenfield, J. Shapiro, V. M. Montori, and B. A. Swiglo
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1105 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E. Elaut, G. De Cuypere, P. De Sutter, L. Gijs, M. Van Trotsenburg, G. Heylens, J.-M. Kaufman, R. Rubens, and G. T'Sjoen
Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels
Eur. J. Endocrinol., March 1, 2008; 158(3): 393 - 399.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III
Increased risk of parkinsonism in women who underwent oophorectomy before menopause
Neurology, January 15, 2008; 70(3): 200 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
P. Roy, M. Alevizaki, and I. Huhtaniemi
In vitro bioassays for androgens and their diagnostic applications
Hum. Reprod. Update, January 1, 2008; 14(1): 73 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. D. Braunstein
The Endocrine Society Clinical Practice Guideline and The North American Menopause Society Position Statement on Androgen Therapy in Women: Another One of Yogi's Forks
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4091 - 4093.
[Full Text] [PDF]

Home page
 NeurologyHome page
W. A. Rocca, J. H. Bower, D. M. Maraganore, J. E. Ahlskog, B. R. Grossardt, M. de Andrade, and L. J. Melton III
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause
Neurology, September 11, 2007; 69(11): 1074 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. A. Ganz and G. A. Greendale
Female Sexual Desire--Beyond Testosterone
J Natl Cancer Inst, May 2, 2007; 99(9): 659 - 661.
[Full Text] [PDF]

Home page
 BMJHome page
H. Roberts
Managing the menopause
BMJ, April 7, 2007; 334(7596): 736 - 741.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Rosner, R. J. Auchus, R. Azziz, P. M. Sluss, and H. Raff
Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 405 - 413.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Practice Guideline: When Is Androgen Therapy Indicated for Women?
Journal Watch (General), November 7, 2006; 2006(1107): 6 - 6.
[Full Text]

eLetters:

Read all eLetters

E-Letter to the Editor: A Different Perspective on Androgen Therapy In Women
Andre T Guay, et al.
JCEM Online, 30 Nov 2006 [Full text]
Re: E-Letter to the Editor: A Different Perspective on Androgen Therapy In Women
Margaret E. Wierman, et al.
JCEM Online, 6 Feb 2007 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society